Vertex Pharmaceuticals, Inc.

Glaxosmithkline LLC

Atai Therapeutics Inc.

Sirtris Pharmaceuticals, Inc.

Empathbio, Inc.

Other

Glaxosmithkline Intellectual Property (no.2) Limited

Immunomolecular Therapeutics, Inc.

Totus Medicines Inc.

Wntrx Pharmaceuticals Inc.

Atai Life Sciences Ag

Van Drie, John H.

Pitlik, Janos

Pernie, Robert B.

Robert B Perni

Janos Pitlik

Kevin Michael Cottrell

Jeremy S Disch

Tanweer A Khan

Glenn Short

Pui Yee Ng

Luc J Farmer

Christopher Oalmann

Chi B Vu

Charles A Blum

Bruce G Szczepankiewicz

John H Van Drie, Jr

Karsten Koppetsch

John J Court

Shawn D Britt

Francois Maltais

Brian H White

Guy W Bemis

Esther Martinborough

John Patrick Maxwell

Upul Keerthi Bandarage

Richard Dana Caldwell

Michael J Arnost

Nicole Zimmermann

Ryan Michael Fox

Rebecca L Casaubon

William Henry Miller

Jean E Bemis

Xicheng David Sun

Govinda Rao Bhisetti

Deqi Guo

Srinivas G Rao

Nancy June Snyder

Frantz Victor

John Irvin Glass

Mark Joseph Tebbe

Q May Wang

Jason Eric Lamar

Cristina Garcia-Paredes

Robert Edward Babine

Yvonne Yee Mai Yip

Ivan Collado

Ling Jin

Raymond Samuel Parker, Iii

Ryan Schutte

James M Siedlecki

Shu Hui Chen

Lawrence F Courtney

Neil Sonin Dhawan

James Abellera Blair

Mark Andrew Murcko

Randy Scott Bethiel

Youssef L Bennani

David D Deininger

Gerald J Tanoury

Keith P Wilson

Gregor Zlokarnik

Minzhang Chen

Young Chun Jung

Dylan H Jacobs

Raymond E Forslund

John Allan Thomson

David Zhu

Alan C Gibbs

Wayne Carl Schairer

Stephanie K Springer

Frank Preugschat

Stephanic K Springer

Srinivas Rao

Benjamin Robert Difrancesco

Summer Halas

Asha Ghevde

John Van Drie

Lauren McPherson

Mohammed Mahmood Ahmed

Cynthia Gates

Ethan O'Malley

Yvonne Angell

Lauren Mcpherson

Brian White

Steve Lyons

Provided herein are compounds of Formula (I), Formula (II), and Formula (III) or pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, Rand A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (II), e.g., in the treatment of a mental health disease or disorder.

Nitric oxide releasing prodrugs of MDA and MDMA

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

Dimethoxyphenylalkylamine activators of serotonin receptors

Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

Aminotetraline activators of serotonin receptors

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

Prodrugs and conjugates of dimethyltryptamine

This disclosure generally relates to therapeutic conjugates that covalently bind to a biological target. Methods of administering the compositions to a subject in need thereof are also provided herein.

Therapeutic conjugates

Provided herein are compounds of Formula (I), (II), or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (II), or a pharmaceutically acceptable salt thereof.

Dimethyltryptamine analogues as nitric oxide delivery drugs

Compounds and compositions useful in methods of treating, ameliorating, or inhibiting the development of an autoimmune disease by modulating the T cell response to antigenic peptide or fragments of antigenic peptides presented by the major histocompatibility (MHC) class II molecule, DQ2.

Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2

Provided herein are compounds of Formula (I), Formula (II), and Formula (III) or pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, Rand A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (III), e.g., in the treatment of a mental health disease or disorder.

The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.

Prodrugs of MDMA, MDA, and derivatives thereof

Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (M-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. 

Disclosed here are polypeptides derived from the HD2 domain of human B-cell CLL/lymphoma 9 (BCL9) protein and variants thereof, as well as their use in the diagnosis, prevention, and/or treatment of a disease or disorder. Also disclosed are methods of generating such polypeptides and variants thereof.

BCL9 peptides and variants thereof

Growing community of inventors

Marlborough, MA, United States of America

Robert B Perni